Dermira price target lowered to $16 from $19 at Needham. Needham analyst Serge Belanger lowered his price target on Dermira to $16 after the company’s inaugural analyst day which focused on the commercial launch strategy for DRM04 to reflect the higher than anticipated launch costs for the program. The analyst keeps his Buy rating however, saying his expectations for FDA approval of DRM04 are high given the “solid” phase 3 data, forecasting the treatment to have a significant role in the hyperhidrosis market which currently has few effective alternatives. Belanger adds that the stock price “undervalues DRM04’s potential and largely ignores the lebrikizumab program”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.